Half-year report · HY
4564.TEDINET S100X054
Period2025-04-01 → 2025-09-30
Filed2025-11-10
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 42
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥432m | 2025-04-01 → 2025-09-30 | Cons. | Net sales |
| Revenue | ¥225m | 2024-04-01 → 2024-09-30 | Cons. | Net sales |
| Operating income | −¥476m | 2025-04-01 → 2025-09-30 | Cons. | Operating income |
| Operating income | −¥531m | 2024-04-01 → 2024-09-30 | Cons. | Operating income |
| Ordinary income | −¥494m | 2025-04-01 → 2025-09-30 | Cons. | Ordinary income |
| Ordinary income | −¥815m | 2024-04-01 → 2025-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | −¥545m | 2024-04-01 → 2024-09-30 | Cons. | Ordinary income |
| Profit before tax | −¥554m | 2025-04-01 → 2025-09-30 | Cons. | Income before income taxes |
| Profit before tax | −¥545m | 2024-04-01 → 2024-09-30 | Cons. | Income before income taxes |
| Net income (owners) | −¥555m | 2025-04-01 → 2025-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥815m | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥546m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | −¥555m | 2025-04-01 → 2025-09-30 | Cons. | Profit loss |
| Net income | −¥546m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss |
| Total assets | ¥1.9bn | at 2025-09-30 | Cons. | Assets |
| Total assets | ¥1.2bn | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥1.5bn | at 2024-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥289m | at 2025-09-30 | Cons. | Liabilities |
| Total liabilities | ¥426m | at 2025-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥1.6bn | at 2025-09-30 | Cons. | Net assets |
| Net assets / equity | ¥729m | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥1.0bn | at 2024-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥1.7bn | at 2025-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥834m | at 2025-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥1.7bn | at 2025-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥834m | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.1bn | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥528m | at 2024-03-31v | Cons. | Cash and cash equivalents |
| Operating cash flow | −¥525m | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥815m | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥579m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥61m | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥279,000 | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | ¥1.4bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥1.1bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥1.1bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥-1.89 | 2025-04-01 → 2025-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-3.12 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-2.18 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 81.4% | at 2025-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 57.0% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 59.9% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 28
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2025-04-01 → 2025-09-30 | −¥185,000 |
| Reconciling Itemsreconciling | revenue intersegment | 2025-04-01 → 2025-09-30 | −¥185,000 |
| Reconciling Itemsreconciling | segment profit | 2025-04-01 → 2025-09-30 | −¥185m |
| Cancer Precision Medical Businessreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥430m |
| Cancer Precision Medical Businessreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥430m |
| Cancer Precision Medical Businessreportable segment | segment profit | 2025-04-01 → 2025-09-30 | −¥7m |
| Research And Development Of Pharmaceutical Productsreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥3m |
| Research And Development Of Pharmaceutical Productsreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥2m |
| Research And Development Of Pharmaceutical Productsreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥185,000 |
| Research And Development Of Pharmaceutical Productsreportable segment | segment profit | 2025-04-01 → 2025-09-30 | −¥284m |
| —segment total | revenue | 2025-04-01 → 2025-09-30 | ¥432m |
| —segment total | revenue external | 2025-04-01 → 2025-09-30 | ¥432m |
| —segment total | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥185,000 |
| —segment total | segment profit | 2025-04-01 → 2025-09-30 | −¥291m |
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2024-09-30 | −¥135,000 |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2024-09-30 | −¥135,000 |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2024-09-30 | −¥178m |
| Cancer Precision Medical Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥222m |
| Cancer Precision Medical Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥222m |
| Cancer Precision Medical Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | −¥94m |
| Research And Development Of Pharmaceutical Productsreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥3m |
| Research And Development Of Pharmaceutical Productsreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥3m |
| Research And Development Of Pharmaceutical Productsreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥135,000 |
| Research And Development Of Pharmaceutical Productsreportable segment | segment profit | 2024-04-01 → 2024-09-30 | −¥259m |
| —segment total | revenue | 2024-04-01 → 2024-09-30 | ¥225m |
| —segment total | revenue external | 2024-04-01 → 2024-09-30 | ¥225m |
| —segment total | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥135,000 |
| —segment total | segment profit | 2024-04-01 → 2024-09-30 | −¥353m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 400
| Item | Context | Value | Unit |
|---|---|---|---|
| Independent auditors report consolidated (text) | FilingDateInstant | Text · Plus | |
| Audit firm1 consolidated | FilingDateInstant | Original text (Japanese)やまと監査法人 | |
| Cpa1 audit firm1 consolidated | FilingDateInstant | Original text (Japanese)木村 喬 | |
| Cpa2 audit firm1 consolidated | FilingDateInstant | Original text (Japanese)遠坂 匡紀 | |
| Number of submission | FilingDateInstant | 1 | |
| Business revenue (5-year summary) | Prior1InterimDuration | 225083000 | JPY |
| Business revenue (5-year summary) | InterimDuration | 431891000 | JPY |
| Business revenue (5-year summary) | Prior1YearDuration | 750048000 | JPY |
| Ordinary income loss (5-year summary) | Prior1InterimDuration | -545169000 | JPY |
| Ordinary income loss (5-year summary) | InterimDuration | -493633000 | JPY |
| Ordinary income loss (5-year summary) | Prior1YearDuration | -815046000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | Prior1InterimDuration | -545699000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | InterimDuration | -555131000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | Prior1YearDuration | -815285000 | JPY |
| Comprehensive income (5-year summary) | Prior1InterimDuration | -545699000 | JPY |
| Comprehensive income (5-year summary) | InterimDuration | -555131000 | JPY |
| Comprehensive income (5-year summary) | Prior1YearDuration | -815285000 | JPY |
| Net assets (5-year summary) | Prior1InterimInstant | 1000348000 | JPY |
| Net assets (5-year summary) | InterimInstant | 1646099000 | JPY |
| Net assets (5-year summary) | Prior1YearInstant | 729111000 | JPY |
| Total assets (5-year summary) | Prior1InterimInstant | 1548092000 | JPY |
| Total assets (5-year summary) | InterimInstant | 1935282000 | JPY |
| Total assets (5-year summary) | Prior1YearInstant | 1155203000 | JPY |
| Basic earnings loss per share (5-year summary) | Prior1InterimDuration | -2.18 | |
| Basic earnings loss per share (5-year summary) | InterimDuration | -1.89 | |
| Basic earnings loss per share (5-year summary) | Prior1YearDuration | -3.12 | |
| Diluted earnings per share (5-year summary) | Prior1InterimDuration | － | |
| Diluted earnings per share (5-year summary) | InterimDuration | － | |
| Diluted earnings per share (5-year summary) | Prior1YearDuration | － | |
| Equity to asset ratio (5-year summary) | Prior1InterimInstant | 0.599 | |
| Equity to asset ratio (5-year summary) | InterimInstant | 0.814 | |
| Equity to asset ratio (5-year summary) | Prior1YearInstant | 0.570 | |
| Net cash provided by used in operating activities (5-year summary) | Prior1InterimDuration | -578766000 | JPY |
| Net cash provided by used in operating activities (5-year summary) | InterimDuration | -525071000 | JPY |
| Net cash provided by used in operating activities (5-year summary) | Prior1YearDuration | -815021000 | JPY |
| Net cash provided by used in investing activities (5-year summary) | Prior1InterimDuration | － | JPY |
| Net cash provided by used in investing activities (5-year summary) | InterimDuration | -60967000 | JPY |
| Net cash provided by used in investing activities (5-year summary) | Prior1YearDuration | -279000 | JPY |
| Net cash provided by used in financing activities (5-year summary) | Prior1InterimDuration | 1149384000 | JPY |
| Net cash provided by used in financing activities (5-year summary) | InterimDuration | 1427378000 | JPY |
| Net cash provided by used in financing activities (5-year summary) | Prior1YearDuration | 1121527000 | JPY |
| Cash and cash equivalents (5-year summary) | Prior1InterimInstant | 1098274000 | JPY |
| Cash and cash equivalents (5-year summary) | InterimInstant | 1675223000 | JPY |
| Cash and cash equivalents (5-year summary) | Prior1YearInstant | 833883000 | JPY |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 338643700 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 338643700 | |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant | 338643700 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant | 338643700 | |
| Number of shares held | InterimInstant_No1MajorShareholdersMember | 19550000 | |
| Shareholding ratio | InterimInstant_No1MajorShareholdersMember | 0.0577 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |